ACCU-CHEK partners with MYLEstone Health to enhance iPhone app Glucose Buddy and web site glucosebuddy.com
Thousands of current users are now testing and logging their blood sugar results in new, more meaningful ways, using ACCU-CHEK Testing in Pairs tool with Glucose Buddy
Thousands of people with iPhones have already downloaded Glucose Buddy, a free app designed to help people with diabetes better manage their disease through a better understanding of what their numbers mean and what they can do to better manage their blood sugar. Now it’s become even easier through a free app upgrade of Glucose Buddy available now.
Roche Diabetes Care, the maker of the ACCU-CHEK line of blood glucose meters and insulin delivery systems, has partnered with MYLEstone Health, the developer of Glucose Buddy and its related web site glucosebuddy.com, to enhance the capabilities of the app. The new version of Glucose Buddy iPhone app and web site now both include ACCU-CHEK Testing in Pairs, an easy-to-use tool that shows the before-and-after effects of meals, activities and other specific events on your blood glucose levels. It is designed for use when you want to focus on one thing in your daily eating habits or routine.
“We are so pleased to be joining forces with MYLEstone Health to offer our Testing in Pairs tool as part of its already highly successful iPhone app Glucose Buddy,” said Roche Vice President of Marketing Dan Kane. “We believe with the addition of the new ACCU-CHEK Testing in Pairs tool, people with diabetes will feel empowered and motivated to make changes based on the simplicity of the tool and the ability to personalize the experience.”
Matthew Tendler, a partner with MYLEstone Health, agrees, stressing that the tool is suitable for both people with Type 1 and Type 2, newly diagnosed or not. “I was diagnosed with Type 1 in 2003 and I thought by now I truly understood what moved my blood sugar numbers – things like going to the gym and eating dessert. But this great tool even helps you determine how your numbers change with everyday activities like taking a walk or playing a round of golf. It’s a great enhancement to Glucose Buddy and applicable to all people with diabetes.”
Kane and Tendler agree this partnership is really the best of both worlds. “We recognized MYLEstone as a company that already has relationships with thousands of Glucose Buddy users on an innovative platform, and we have a useful tool to offer people with diabetes that can help them take the self-management of their condition a step or two further,” Kane said.
Current users of Glucose Buddy will receive a personalized email from Tendler, along with a prompt to visit the APP Store for an upgrade.
About MYLEstone Health
MYLEstone Health is a leading developer of health-based mobile applications aimed at Making Your Life Easier through advanced software functionality and motivation tools. iPhone App utilities include data storage, health information services, education, notifications and social networking. Glucose Buddy by MYLEstone Health is the most popular diabetes specific App for the iPhone. For more information, visit www.glucosebuddy.com.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients’ condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management—from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems. For more information, please visit accu-chek.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R & D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us.
All trademarks used or mentioned in this release are protected by law.
For further information, please contact: